RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

Novartis (NVS) announced on Friday that, following regulatory feedback, it has withdrawn its EU marketing application for Pluvicto, which aimed at broadening the use of the radiotherapy for a specific ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate ...

HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 ...

SAN FRANCISCO -- Combining a PARP inhibitor with an androgen receptor pathway inhibitor as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer ...

Doxetaxel recharge was associated with a 3.3-month benefit in OS and a 1.8-month improvement in time to subsequent treatment or death. Docetaxel rechallenge improved overall survival compared with ...

Olaparib monotherapy demonstrates clinical benefit despite use in later lines of therapy in a real-world study of patients with mCRPC and human recombinant repair gene mutations. Several lines of ...